JP2013531006A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013531006A5 JP2013531006A5 JP2013517611A JP2013517611A JP2013531006A5 JP 2013531006 A5 JP2013531006 A5 JP 2013531006A5 JP 2013517611 A JP2013517611 A JP 2013517611A JP 2013517611 A JP2013517611 A JP 2013517611A JP 2013531006 A5 JP2013531006 A5 JP 2013531006A5
- Authority
- JP
- Japan
- Prior art keywords
- depression
- disorder
- alkyl
- pharmaceutically acceptable
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36250510P | 2010-07-08 | 2010-07-08 | |
| US61/362,505 | 2010-07-08 | ||
| PCT/IB2011/052686 WO2012004698A1 (en) | 2010-07-08 | 2011-06-20 | Piperidinyl pyrimidine amides as kv7 potassium channel openers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013531006A JP2013531006A (ja) | 2013-08-01 |
| JP2013531006A5 true JP2013531006A5 (OSRAM) | 2014-06-05 |
| JP5763758B2 JP5763758B2 (ja) | 2015-08-12 |
Family
ID=44487037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013517611A Expired - Fee Related JP5763758B2 (ja) | 2010-07-08 | 2011-06-20 | Ｋｖ７カリウムチャネル開口薬としてのピペリジニルピリミジンアミド |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8883812B2 (OSRAM) |
| EP (1) | EP2590961A1 (OSRAM) |
| JP (1) | JP5763758B2 (OSRAM) |
| KR (1) | KR101449348B1 (OSRAM) |
| CN (1) | CN102971307A (OSRAM) |
| AU (1) | AU2011275393B2 (OSRAM) |
| CA (1) | CA2804165C (OSRAM) |
| MX (1) | MX2013000138A (OSRAM) |
| SG (1) | SG186409A1 (OSRAM) |
| WO (1) | WO2012004698A1 (OSRAM) |
| ZA (1) | ZA201300499B (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013067591A1 (en) * | 2011-11-10 | 2013-05-16 | Relevare Australia Pty Ltd | Topical formulations for pain management |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| ES2885424T3 (es) | 2013-03-15 | 2021-12-13 | Knopp Biosciences Llc | Imidazo(4,5-B)piridin-2-il amidas como activadores del canal Kv7 |
| ES2960991T3 (es) | 2014-09-12 | 2024-03-07 | Biohaven Therapeutics Ltd | Benzoimidazol-1,2-ilamidas como activadores del canal Kv7 |
| JP7121144B2 (ja) * | 2018-02-20 | 2022-08-17 | ハー・ルンドベック・アクチエゼルスカベット | Ｋｖ７カリウムチャネル開口薬としてのアルコール誘導体 |
| IL310136A (en) | 2018-03-19 | 2024-03-01 | Knopp Biosciences Llc | KV7 channel activator preparations and methods of use |
| AR119521A1 (es) * | 2019-08-02 | 2021-12-22 | H Lundbeck As | DERIVADOS DE ALCOHOL COMO ABRIDORES DEL CANAL DE POTASIO Kv7 |
| AU2020350614A1 (en) * | 2019-09-17 | 2022-03-31 | Biohaven Therapeutics Ltd. | Methods of use for Kv7 channel activators |
| WO2021119018A1 (en) * | 2019-12-09 | 2021-06-17 | The Board Of Trustees Of The Leland Stanford Junior University | A method to improve sleep quality in the elderly by controlling excitability of hypocretin neurons |
| WO2021211867A1 (en) * | 2020-04-16 | 2021-10-21 | Attune Neurosciences, Inc. | Kv7 modulators for treating sleep or anxiety disorders |
| WO2022047311A1 (en) * | 2020-08-28 | 2022-03-03 | Pfizer Inc. | Computerized decision support tool and medical device for respiratory condition monitoring and care |
| GB202306914D0 (en) * | 2023-05-10 | 2023-06-21 | Sania Rx Ltd | Method |
| CN119661413B (zh) * | 2024-12-28 | 2025-06-24 | 齐鲁医药学院 | Kv7钾离子通道开放剂及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1361879A1 (en) * | 2001-02-20 | 2003-11-19 | Bristol-Myers Squibb Company | 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators |
| TWI349666B (en) | 2004-03-12 | 2011-10-01 | Lundbeck & Co As H | Substituted morpholine and thiomorpholine derivatives |
| US7091202B2 (en) * | 2004-09-15 | 2006-08-15 | Bristol-Myers Squibb Company | 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators |
| US20080261918A1 (en) * | 2004-12-17 | 2008-10-23 | Graham Andrew Showell | Silicon Compounds and Their Use |
| US7322249B2 (en) | 2005-07-07 | 2008-01-29 | Delphi Technologies, Inc. | Mounting for a probe sensor |
| AU2006322461A1 (en) * | 2005-09-09 | 2007-06-14 | H. Lundbeck A/S | Pyrimidine derivatives and their use as KCNQ potassium channels openers |
| US7683058B2 (en) * | 2005-09-09 | 2010-03-23 | H. Lundbeck A/S | Substituted pyrimidine derivatives |
| US20090118285A1 (en) | 2006-02-07 | 2009-05-07 | H. Lundbeck A/S | Use of kcnq-openers for treating or reducing the symptoms of schizophrenia |
| BRPI0716715B1 (pt) * | 2006-08-23 | 2021-07-06 | Xenon Pharmaceuticals, Inc | Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potássio, seus usos, produto, composição, comprimido e cápsula |
| US8367684B2 (en) * | 2007-06-13 | 2013-02-05 | Valeant Pharmaceuticals International | Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators |
| EP2185149A1 (en) | 2007-08-01 | 2010-05-19 | H. Lundbeck A/S | Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted |
-
2011
- 2011-06-20 JP JP2013517611A patent/JP5763758B2/ja not_active Expired - Fee Related
- 2011-06-20 EP EP11738482.6A patent/EP2590961A1/en not_active Withdrawn
- 2011-06-20 WO PCT/IB2011/052686 patent/WO2012004698A1/en not_active Ceased
- 2011-06-20 KR KR1020137000377A patent/KR101449348B1/ko not_active Expired - Fee Related
- 2011-06-20 US US13/808,355 patent/US8883812B2/en not_active Expired - Fee Related
- 2011-06-20 AU AU2011275393A patent/AU2011275393B2/en not_active Ceased
- 2011-06-20 MX MX2013000138A patent/MX2013000138A/es active IP Right Grant
- 2011-06-20 CA CA2804165A patent/CA2804165C/en not_active Expired - Fee Related
- 2011-06-20 CN CN2011800337518A patent/CN102971307A/zh active Pending
- 2011-06-20 SG SG2012093761A patent/SG186409A1/en unknown
-
2013
- 2013-01-18 ZA ZA2013/00499A patent/ZA201300499B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11224573B2 (en) | Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor | |
| JP2017513942A (ja) | Ｍｅｒｔｋ特異的ピロロピリミジン化合物 | |
| AU2022298639C1 (en) | Diacylglyercol kinase modulating compounds | |
| EP4359413A1 (en) | Diacylglyercol kinase modulating compounds | |
| JP2015504067A5 (OSRAM) | ||
| US20240199596A1 (en) | Diacylglycerol kinase modulating compounds | |
| JP2014532768A5 (OSRAM) | ||
| ES2362637T3 (es) | Combinaciones antitumorales que contienen un agente inhibidor de vegf y de irinotecan. | |
| JP2013504536A5 (OSRAM) | ||
| JP2013518036A5 (OSRAM) | ||
| KR20140025461A (ko) | 진행성 고형 종양의 치료 방법 | |
| JP2019533682A (ja) | 抗ｃｄ１９抗体とｂｃｌ−２阻害剤との組み合わせおよびその使用 | |
| AU2020343329C1 (en) | Methods of treatment | |
| CA2476825A1 (en) | Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases | |
| US11464805B2 (en) | CCR2+ hematopoietic stem cells mediate T cell activation in adoptive cell therapy | |
| JP5548874B2 (ja) | がん免疫抑制解除剤及びがん免疫治療用組成物 | |
| RU2015120651A (ru) | Производные имидазопиридина | |
| JP2024511057A5 (OSRAM) | ||
| JP2024511997A5 (OSRAM) | ||
| WO2008060535A2 (en) | Use of reversine and analogs for treatment of cancer | |
| CN119584963A (zh) | 使用bcl-2抑制剂治疗多发性骨髓瘤的方法 | |
| US20110281813A1 (en) | Method of treating c-kit positive relapsed acute myeloid leukemia | |
| US20150110864A1 (en) | Novel antitumor agent comprising combination of three agents | |
| JP2005501846A (ja) | 新規組合せ製品 | |
| HK40066948A (zh) | 治疗方法 |